Search Results
Your search for it matches 15485 pages
Showing 1651 - 1700Patients With Brain Metastases From Renal Cell Carcinoma May Have Distinct Immunosuppressive Tumor Microenvironment
Researchers have created the largest single-cell atlas of renal cell carcinoma brain metastases, with matched primary and extracranial metastases, which has potentially enabled them to discover key biological mechanisms contributing to an immunosuppressive tumor microenvironment in the brain...
Study Identifies Mutations That May Be Associated With Poor Outcomes in Patients With NSCLC Treated With KRAS G12C Inhibitors
Researchers have discovered that co-occurring mutations in three tumor-suppressor genes—KEAP1, SMARCA4, and CDKN2A—may be linked with poor clinical outcomes in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) who were treated with the KRAS G12C inhibitors adagrasib or sotorasib,...
Whole-Exome Sequencing May Help Identify Individuals With Cancer Predisposition Syndromes Missed by Current Screening Guidelines
Researchers revealed that 39.2% of patients who consented to whole-exome sequencing and were identified as carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome did not qualify for genetic screening under current guidelines, according to new findings presented...
Investigational Deep Learning Model May Help Stratify Risk of Distant Recurrence in Patients With Endometrial Cancer
An investigational deep learning model requiring one histopathologic slide may be effective at predicting the risk of distant recurrence in patients with endometrial cancer, according to novel findings presented by Fremond et al at the American Association for Cancer Research (AACR) Annual Meeting...
Olaparib Plus Ceralasertib May Benefit Pediatric Patients With Cancer Who Have DNA Replication and/or Damage Repair–Deficient Tumors
Researchers have found that a combination of the PARP inhibitor olaparib and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication and/or damage repair deficiencies, according to new findings presented by Gatz et al ...
Immune Checkpoint Inhibition and Long-Term Survival in Patients With Metastatic Urothelial Cancer
In an analysis reported in JAMA Network Open, Zhu et al found that immune checkpoint inhibitor treatment did not appear to be associated with long-term survival in patients with metastatic urothelial cancer. Study Details The analysis included data from six trials of pembrolizumab, avelumab, and...
Awareness of the Link Between HPV and Cervical Cancer Has Declined Between 2014 and 2020
Americans have become less aware that the human papillomavirus (HPV) causes cervical cancer in recent years, according to survey data presented by Adjei Boakye et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract 4210 /11). Survey respondents also showed low...
Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma
Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by Kendra et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract...
Personalized mRNA-Based Cancer Vaccine Plus Pembrolizumab for High-Risk Melanoma
mRNA-4157/V940, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor pembrolizumab improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma, and clinical benefit was observed regardless of tumor mutational...
Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC: AEGEAN Trial
Treatment-naive patients with resectable non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response compared with those who received neoadjuvant chemotherapy alone,...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Update on Withdrawal of Ibrutinib Accelerated Approvals for MCL and MZL in the United States
AbbVie announced that it intends to voluntarily withdraw, in the United States, accelerated ibrutinib (Imbruvica) approvals for patients with mantle cell lymphoma (MCL) who have received at least one prior therapy as well as patients with marginal zone lymphoma (MZL) who require systemic therapy...
Pragmatica-Lung Trial Begins Enrolling Patients With NSCLC Who Did Not Respond to Previous Therapy
The National Cancer Institute (NCI) announced that it has helped launch the randomized phase III Pragmatica-Lung trial examining the efficacy of ramucirumab plus pembrolizumab in treating patients with advanced non–small cell lung cancer (NSCLC). The new study is one of the first NCI-supported...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Cancer Susceptibility Germline Pathogenic Variants Among Older Patients
Hereditary cancer syndromes are caused by a pathogenic variant in cancer susceptibility genes, which overall account for approximately 10% of all cancers. Carriers of pathogenic variants are at an increased risk of developing cancer during their lifetime. Genomic cancer risk assessment makes it...
Novel Device May Be Safe, Effective Chemotherapy Delivery System for Patients With Muscle-Invasive Bladder Cancer Who Are Unfit for Standard Therapy
Researchers have found that the novel intravesical chemotherapy delivery system TAR-200 may be safe and effective for patients with advanced muscle-invasive bladder cancer who are medically unfit for standard treatment, according to a new study published by Tyson et al in The Journal of Urology....
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Prior CTLA-4 Inhibition May Influence Response to PD-1 Inhibitors in Patients With Advanced Melanoma
Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. “In our large set of data, features that have...
Combination Therapy May Help Patients With KMT2A-Mutated ALL or AML Overcome BET Inhibitor Resistance
Researchers have developed a novel combination therapy approach to help patients with KMT2A-mutated acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) overcome resistance to bromodomain and extraterminal domain (BET) inhibitors without adding toxicity, according to a novel study...
Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases
Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...
Pathologic Complete Response as Surrogate for Event-Free and Overall Survival in Neoadjuvant Trials in HER2-Positive Early Breast Cancer
In a study reported in the Journal of Clinical Oncology, Squifflet et al found that pathologic complete response (pCR) was a weak surrogate for event-free and overall survival in neoadjuvant trials of anti-HER2 therapy in patients with HER2-positive early breast cancer. Study Details In the study,...
Azacitidine in Combination With Trametinib May Be Effective for Pediatric Patients With JMML
Researchers have found that the hypomethylating agent azacitidine plus the MEK inhibitor trametinib may be a promising new combination to treat patients with juvenile myelomonocytic leukemia (JMML), according to a preclinical study published by Pasupuleti et al in Molecular Therapy. Background JMML ...
City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System
City of Hope in Duarte, California, recently announced that its subsidiary, Cancer Treatment Centers of America (CTCA), will fully transition its clinical locations to City of Hope’s brand. CTCA locations in different cities will now be called City of Hope Atlanta, City of Hope Chicago, and City of ...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Genetics Likely Caused My Small Cell Lung Cancer
When I was diagnosed with lung cancer, in 2007, I asked the physician not to tell me the type, stage, or prognosis. I was about to start nursing school and was aware enough about the disease to know that not many people survived. I’ve since discovered that I had stage 3B small cell lung cancer,...
Abemaciclib Expanded Indication for Adjuvant Use in HR-Positive, HER2-Negative, Node-Positive Early Breast Cancer
On March 3, 2023, abemaciclib was approved for use with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.1 Abemaciclib was previously approved...
President Biden Prioritizes Cancer Research, Access to Care in FY 2024 Budget Proposal
On March 9, 2023, President Joseph Biden released his proposed Fiscal Year (FY) 2024 federal budget, with an emphasis on increased funding for medical research and expanded access to health insurance. The proposal allocates $48.3 billion for the National Institutes of Health (NIH), an $811 million ...
Summing It Up: Neoadjuvant Therapy in Triple-Negative Disease
Here is how Dr. Sharma summed up the current state of neoadjuvant therapy in triple-negative breast cancer: The addition of an immune checkpoint inhibitor to neoadjuvant chemotherapy improves long-term outcomes. This strategy can produce a modest improvement in pathologic complete response and a...
Which Patients With Breast Cancer Can Omit Radiotherapy?
Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...
Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy
The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery at the Medical College of Wisconsin, highlighted the significance of the 80% response rates to neoadjuvant immunotherapy in primary...
Highlights of Novel Therapies Under Study in Genitourinary Cancers
Here are some brief reports from the 2023 ASCO Genitourinary (GU) Cancers Symposium that we hope are of interest. They include real-world evidence about the use of avelumab maintenance in metastatic urothelial carcinoma, data on the feasibility of sequencing radium-223 and Lu-177–PSMA-617 in...
Study Examines Utility, Accuracy of ChatGPT in Offering Breast Cancer Screening Recommendations
A new study suggests that the answers generated by the artificial intelligence (AI) chatbot ChatGPT may provide correct breast cancer screening advice the vast majority of the time; however, the information is sometimes inaccurate or even fictitious, according to the report published by Haver et al ...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Addressing Health Disparities in Oncology Care—Legally and Ethically
A health disparity is typically defined as involving a differential in health outcomes between some groups of patients and other groups, for example, between White and Black patients, in which some groups fare better than others. Health inequities are commonly defined as health differences that...
Expert Point of View: Oliver Sartor, MD
The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...
HHS Releases National Cancer Plan to Advance the Goals of the Cancer Moonshot and Improve Outcomes for All Patients
On April 3, the U.S. Department of Health and Human Services (HHS) released a National Cancer Plan, which calls for collaboration to realize the objectives laid out in the Cancer Moonshot to reduce cancer mortality by at least 50% over the next 25 years and “end cancer as we know it.” Developed by...
More U.S. Patients With Prostate Cancer May Be Electing for Active Surveillance
Since 2010, investigators have discovered that the number of patients with prostate cancer in the United States who are choosing active surveillance over surgery or radiation therapy may be rapidly increasing, according to a new study published by Al Awamlh et al in JAMA Internal Medicine....
ChatGPT May Have Potential to Help Educate Patients With Cirrhosis and Hepatic Cancer in Basic Knowledge, Lifestyle, and Treatment Domains
Investigators revealed that the artificial intelligence (AI) chatbot ChatGPT may help improve health outcomes for patients with cirrhosis and hepatic cancer by providing easy-to-understand information about basic knowledge, lifestyle modifications, and treatment options for these conditions,...
Initiative for Managing Adverse Events of Immunotherapy Leads to Clinical Practice Changes at MD Anderson
The inaugural MD Anderson Clinical Education Symposium on Immunotherapy Toxicity Management (IOTOX) welcomed more than 250 international attendees, both virtually and in person at The University of Texas MD Anderson Cancer Center in Houston on December 3, 2022. The symposium focused on bringing the ...
How Effectively Are You Helping Patients With Cancer at the End of Life?
“Providing hope when there is little to hope for is hard,” noted Hyman B. Muss, MD, Professor of Medicine and the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center. At the 2023 Miami...
CAR T-Cell Therapy May Improve Quality of Life of Patients With Hematologic Malignancies
Patients with hematologic malignancies may experience a significant improvement in their reported quality of life 6 months after receiving chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Johnson et al in Blood Advances. Background Although CAR T-cell therapy...
Study Assesses Prevalence, Severity, and Co-occurrence of Common Symptoms That May Be Undertreated in Patients With Cancer
Investigators have revealed the findings from an examination of the prevalence, severity, and co-occurrence of sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy/fatigue (SPPADE) symptoms, as well as their association with different cancer types and patient...
Nivolumab Injected Directly Into Spinal Fluid May Be Safe and Effective for Some Patients With Melanoma Who Have Leptomeningeal Disease
Researchers have found that a novel approach to administer intrathecal and intravenous nivolumab has proven safe and improved survival in a subset of patients who developed leptomeningeal disease from metastatic melanoma, according to a new study published by Glitza Olivia et al in Nature ...
Researchers Uncover How Advanced Melanoma May Resist Treatment at the End of Life
Researchers have revealed the potential mechanisms contributing to treatment resistance in patients with melanoma at the end of life, according to a new study published by Spain et al in Cancer Discovery. “These results present the most detailed picture yet of what melanoma looks like at the final...
Addition of Gemcitabine to Cisplatin and Intensity-Modulated Radiation Therapy May Improve Outcomes for Patients With Locally Advanced Vulvar Cancer
Researchers have found that concurrent treatment with gemcitabine as well as cisplatin and intensity-modulated radiation therapy may effectively increase the pathologic complete response rates in patients with locally advanced squamous cell carcinoma of the vulva, according to findings presented by ...
Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods
In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....
Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo
Researchers have found no significant differences in overall survival between patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib or placebo, according to new findings presented by Matulonis et...
Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse events, and positive health outcomes in patients with ovarian cancer who have a germline...
